Financhill
Sell
46

VSTM Quote, Financials, Valuation and Earnings

Last price:
$6.94
Seasonality move :
14.67%
Day range:
$6.35 - $6.71
52-week range:
$2.10 - $13.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
27.44x
Volume:
669.5K
Avg. volume:
1.1M
1-year change:
-41.42%
Market cap:
$344.5M
Revenue:
$10M
EPS (TTM):
-$3.72

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VSTM
Verastem
$100K -$0.78 -53% -145.16% $13.38
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.17 -- -67.93% --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VSTM
Verastem
$6.69 $13.38 $344.5M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.24 -- $19.4M -- $0.00 0% --
OGEN
Oragenics
$0.17 $1.00 $3.7M -- $0.00 0% 1.06x
PTN
Palatin Technologies
$0.09 -- $2.4M -- $0.00 0% --
TOVX
Theriva Biologics
$0.81 $6.00 $2.3M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VSTM
Verastem
50.52% -1.377 40.34% 3.10x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
PTN
Palatin Technologies
-- 1.358 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VSTM
Verastem
-- -$31.6M -78.01% -120.71% -71.18% -$25.1M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$3.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -- -- -- -- --
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Verastem vs. Competitors

  • Which has Higher Returns VSTM or NBY?

    NovaBay Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of -49.65%. Verastem's return on equity of -120.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$1.55 $80.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About VSTM or NBY?

    Verastem has a consensus price target of $13.38, signalling upside risk potential of 99.93%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Verastem has higher upside potential than NovaBay Pharmaceuticals, analysts believe Verastem is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is VSTM or NBY More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock VSTM or NBY?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or NBY?

    Verastem quarterly revenues are $10M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verastem's net income of -$64.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Verastem's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$64.6M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns VSTM or NNVC?

    Nanoviricides has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$1.55 $80.9M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About VSTM or NNVC?

    Verastem has a consensus price target of $13.38, signalling upside risk potential of 99.93%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 424.19%. Given that Nanoviricides has higher upside potential than Verastem, analysts believe Nanoviricides is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is VSTM or NNVC More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock VSTM or NNVC?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or NNVC?

    Verastem quarterly revenues are $10M, which are larger than Nanoviricides quarterly revenues of --. Verastem's net income of -$64.6M is lower than Nanoviricides's net income of -$2M. Notably, Verastem's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$64.6M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns VSTM or OGEN?

    Oragenics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$1.55 $80.9M
    OGEN
    Oragenics
    -- -$0.27 --
  • What do Analysts Say About VSTM or OGEN?

    Verastem has a consensus price target of $13.38, signalling upside risk potential of 99.93%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 488.24%. Given that Oragenics has higher upside potential than Verastem, analysts believe Oragenics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    OGEN
    Oragenics
    0 1 0
  • Is VSTM or OGEN More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock VSTM or OGEN?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or OGEN?

    Verastem quarterly revenues are $10M, which are larger than Oragenics quarterly revenues of --. Verastem's net income of -$64.6M is lower than Oragenics's net income of -$3.3M. Notably, Verastem's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 1.06x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$64.6M
    OGEN
    Oragenics
    1.06x -- -- -$3.3M
  • Which has Higher Returns VSTM or PTN?

    Palatin Technologies has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$1.55 $80.9M
    PTN
    Palatin Technologies
    -- -- --
  • What do Analysts Say About VSTM or PTN?

    Verastem has a consensus price target of $13.38, signalling upside risk potential of 99.93%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Verastem, analysts believe Palatin Technologies is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    PTN
    Palatin Technologies
    0 0 0
  • Is VSTM or PTN More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

  • Which is a Better Dividend Stock VSTM or PTN?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or PTN?

    Verastem quarterly revenues are $10M, which are larger than Palatin Technologies quarterly revenues of --. Verastem's net income of -$64.6M is higher than Palatin Technologies's net income of --. Notably, Verastem's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$64.6M
    PTN
    Palatin Technologies
    -- -- -- --
  • Which has Higher Returns VSTM or TOVX?

    Theriva Biologics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VSTM
    Verastem
    -- -$1.55 $80.9M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About VSTM or TOVX?

    Verastem has a consensus price target of $13.38, signalling upside risk potential of 99.93%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 640.74%. Given that Theriva Biologics has higher upside potential than Verastem, analysts believe Theriva Biologics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    VSTM
    Verastem
    7 0 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is VSTM or TOVX More Risky?

    Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock VSTM or TOVX?

    Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VSTM or TOVX?

    Verastem quarterly revenues are $10M, which are larger than Theriva Biologics quarterly revenues of --. Verastem's net income of -$64.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Verastem's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VSTM
    Verastem
    -- -- $10M -$64.6M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 6.67% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock